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Abstract 
Background: Informed consent is required for participation in clinical trials, however trials involving adults who lack 
capacity to consent require different enrolment processes. A family member usually acts as a proxy to make a deci-
sion based on the patient’s ‘presumed will’, but these decisions can be challenging and families may experience an 
emotional and decisional burden. Decisions made on behalf of others are conceptually different from those made for 
ourselves. Innovations have been developed to improve informed consent processes for research, including a number 
of decision aids, however there are no interventions for proxies who are faced with more complex decisions. This 
article outlines the development of a novel decision aid to support families making decisions about research partici-
pation on behalf of an adult who lacks capacity to consent.
Methods: Decision support interventions should be developed using rigorous and evidence-based methods. This 
intervention was developed using MRC guidance for the development of complex interventions, and a conceptual 
framework for the development and evaluation of decision aids for people considering taking part in a clinical trial. 
The intervention was informed by a systematic review and analysis of existing information provision. Previous qualita-
tive research with families who acted as proxies enabled the development of a theoretical framework to underpin 
the intervention. The intervention was iteratively developed with the involvement of lay advisors and relevant 
stakeholders.
Results: Previous research, theoretical frameworks, and decision aid development frameworks were used to identify 
and develop the intervention components. The decision aid includes information about the proxy’s role and utilises 
a values clarification exercise and decision support methods to enable a more informed and better-quality decision. 
Stakeholders, including those representing implementers and receivers of the intervention, contributed to the design 
and comprehensibility of the decision aid to ensure that it would be acceptable for use.
Conclusions: Frameworks for the development of decision aids for people considering participating in a clinical trial 
can be used to develop interventions for family members acting as proxy decision-makers. The decision support tool 
is acceptable to users. Feasibility testing and outcome measure development is required prior to any evaluation of its 
effectiveness.
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Background
Informed consent is considered to be the cornerstone 
of ethically conducted medical research [1, 2]. However, 
there are times when patients are unable to provide con-
sent for themselves due to a cognitive impairment, which 
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may be associated with a neurodegenerative condition 
such as dementia or resulting from an acute medical 
emergency or accident. Adults considered to be unable 
to make a particular decision for themselves at the time 
the decision or action needs to be taken are described as 
lacking decision-making capacity (Part 1 (2(1) and (2)) 
[3]. In England and Wales an assessment process laid 
down in the Mental Capacity Act 2005 is used to deter-
mine whether someone has capacity to make a particular 
decision [3]. Where a potential research participant lacks 
capacity to consent, someone close to the patient, usually 
a family member, is approached to make a decision about 
research participation on their behalf.
Arrangements governing who is legally authorised to 
decide about enrolment in research differ across legal 
jurisdictions and may also vary according to the type of 
research. In England and Wales, the Mental Capacity 
Act 2005 (MCA) governs most types of research and has 
provision for consulting someone who knows the person 
with impaired capacity well to act as consultee and advise 
about research participation on their behalf [3]. The 
family member or friend acting as consultee is provided 
with information about the project and asked what the 
patient’s likely wishes and feelings would be about taking 
part in the project if he or she had capacity [3]. However, 
responsibility for deciding whether to include the patient 
lies ultimately with the researcher [3]. For clinical trials of 
investigational medicinal products (CTIMPs), the Medi-
cines for Human Use (Clinical Trials) Regulations 2004 
(CTR) applies across the UK [4]. Under the CTR, the 
family member or friend is termed a legal representative 
and provides informed consent on behalf of the patient 
based on what they would have wanted had they the 
capacity to choose for themselves, their ‘presumed will’ 
[4]. The term proxy is used in this paper to include both 
consultees and legal representatives.
Previous research has shown that whilst families are 
supportive of being involved in proxy decisions about 
research [5], it can be a difficult task [6]. Family members 
are responsible for making a decision that may potentially 
have far-reaching consequences for the health and wel-
fare of another person. Proxies are acutely aware of the 
moral difference between deciding for themselves and 
deciding for others [7], and may experience an emotional 
and decisional burden as a result. A recent systematic 
review of proxy decision-making for research found that 
the weight of making a decision on behalf of another per-
son, together with the uncertainty about how decisions 
ought to be made by proxies, is burdensome for proxies 
[8]. One study reported that nearly all proxies experience 
some degree of burden when making decisions about 
research [6]. Our recent qualitative study found that 
making decisions about research was problematic for 
some proxies who were concerned about making what 
they considered to be the ‘right’ decision for the person 
they represented [9]. The study found that some proxies 
may benefit from decision support in order to make an 
informed decision about research participation [9].
Decision support interventions for research participation 
decisions
Decision support interventions, also known as decision 
aids (DAs) are interventions that are increasingly being 
used to support patients who are making choices about 
their healthcare by making their decisions explicit, and 
providing information about their options and the associ-
ated benefits and harms [10]. DAs differ from traditional 
information materials in many ways, including that they 
are not narrowly focused on improving the delivery of 
information [11] nor intended to encourage a particular 
choice or action [12] but are intended to facilitate patient 
involvement in decisions, leading to decisions which are 
informed and consistent with their own values [13, 14]. 
DAs can take many forms, for example a paper-based 
booklet, video, or web-based tool [15]. More recently, 
decision aids have been developed for decisions about 
participation in trials [16], however proxy decisions 
about research have not previously been considered a 
target for improvement.
In health care, patients’ decisions about treatment 
and screening are often described as ‘preference sensi-
tive’, where the relative importance a patient attaches 
to various outcomes and processes has a large, if not 
determining, influence on what is decided [17]. Qual-
ity decision-making is therefore said to be the extent to 
which the chosen option matches the informed decision-
maker’s values for benefits, harms, and uncertainties [18]. 
The effectiveness of DAs on improving decisions (making 
them ‘good’ decisions) can be viewed as influencing two 
constructs: (i) the quality of the decision-making process 
and (ii) the quality of the choice that is made (i.e. decision 
quality) [19]. There is growing evidence of the effective-
ness of DAs in improving both the quality of the deci-
sion-making process and decision quality for healthcare 
decisions [19]. A recent Cochrane review established that 
decision aids can improve knowledge, reduce decisional 
conflict, clarify expectations of possible benefits and 
harms, lead to choices consistent with informed values, 
and result in greater participation in decision making 
[10].
A small number of interventions have been developed 
to promote informed decision-making about participa-
tion in clinical trials [20–22]. Of the small number of 
DAs that aim to improve decision-making for trial par-
ticipation (rather than aiming to solely improve the pres-
entation of information or mode of delivery) most focus 
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on specific oncology trials [11]. These DAs show some 
potential promise in improving key decision outcomes 
such as knowledge, values clarification, and decision con-
flict, while not negatively impacting recruitment or inten-
tion to participate [20, 21, 23]. A recent systematic review 
of decision aids for trials only identified one study that 
evaluated the effectiveness of decision aids compared to 
standard information in the informed consent process 
for clinical trials [16]. The reviewers concluded that more 
high quality randomised controlled trials of decision aids 
to support the informed consent process for clinical trials 
are needed [16]. In non-oncology conditions, a qualita-
tive exploration of stakeholders’ perceptions of decision 
aids for randomised controlled trials that are currently 
in development suggested that decision aids have the 
potential to better engage potential participants in the 
decision-making process and allow them to make more 
personally relevant decisions about their participation 
[24].
Need for decision support interventions for proxy 
decisions about research participation
Despite these innovations to improve informed consent 
decisions, and proxy decisions about healthcare (e.g. for 
people living with dementia [25]) there are no interven-
tions for proxies making decisions about research par-
ticipation which, it could be argued, are more complex 
decisions. Legal and ethical frameworks require proxy 
decisions about research participation to be based on 
what the wishes and feelings of the person lacking capac-
ity to consent would be about taking part in the study 
[3] or, for a clinical trial, representing their ‘presumed 
will’ [4]. This requires the proxy to first determine what 
the wishes and preferences of the person they are rep-
resenting would be about participating, and then make 
a decision based on this determination. Proxy decisions 
can therefore also be viewed as preference sensitive deci-
sions, but they are based on the patient’s preferences and 
values rather than their own. Whilst some patients may 
have discussed their preferences about participating in 
any research in the event of a loss of capacity to consent, 
in practice very few will have done so [8], and so making 
a decision that represents their wishes may be challeng-
ing for proxies. Interventions to reduce the burden and 
decisional conflict experienced by proxies are needed in 
order to support family members through what can be an 
emotional and challenging decision [9], and so may help 
address the current exclusion of adults who lack capacity 
from research [26].
A DA for proxy decision-makers could improve the 
decision-making process through helping the proxy 
determine what the person’s preferences would be, 
and decision quality by ensuring that the choice made 
matches those preferences. As there is a lack of a DA 
for proxy decisions about research, and DAs are deci-
sion‐specific interventions that are unlikely to produce 
a benefit in other decision contexts [27], development 
of a decision-specific intervention is needed. This paper 
describes the development of a novel intervention to 
support decision-making by family members when mak-
ing decisions about research participation on behalf of a 
patient who lacks capacity to consent.
Methods
Development of the decision support intervention
As the interest in DAs for trial participation grows, so 
does the importance that their development is both rig-
orous and evidence-based [11]. The development of 
this DA for proxy decision-making was informed by a 
recently proposed framework for the development and 
evaluation of decision aids for people considering taking 
part in a clinical trial [11]. The framework proposed by 
Gillies and Campbell consists of five steps: (1) selecting 
an underpinning theoretical approach to the develop-
ment process; (2) developing the decision aid; (3) assess-
ing and testing feasibility; (4) evaluating the decision aid; 
and (5) implementing the decision aid in practice [11]. 
The first two steps of the framework are reported in this 
paper and an overview of the process is outlined in Fig. 1.
Results
Phase 1: identify relevant intervention development 
frameworks
The initial phase of the development process was to iden-
tify appropriate frameworks that inform the development 
of complex interventions in general, and then those spe-
cifically for decision aid interventions from both a theo-
retical and practical perspective.
Intervention development frameworks
The Medical Research Council (MRC) framework for 
developing and evaluating complex interventions is 
widely used [28]. It describes an iterative process of devel-
opment, feasibility/piloting, evaluation, and implementa-
tion of interventions [28], however, it has limited detailed 
guidance for the development phase itself. Recently, a 
model which focuses on the intervention development 
phase (6Squid) has been developed which describes how 
the process can be broken down into six steps, although 
in practice the process is non-linear and collaborative 
[29]. Researchers have proposed combining the ele-
ments of the development phase of the MRC Frame-
work with elements of the 6Squid model to enhance the 
intervention development through a more comprehen-
sive approach. This ‘enriching’ approach to the develop-
ment phase [30] has been used for the development this 
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decision support intervention. The methods used in the 
6Squid steps are shown in Table 1.
Decision aid development frameworks
The Ottawa Decisional Support Framework (ODSF), 
which is an evidence-based, practical, mid-range theory 
for guiding patients making health or social decisions, 
Fig. 1 Intervention development process flow diagram
Table 1 Six steps in development of the decision aid intervention
a Feasibility study to be conducted as part of a follow-on project
Step in intervention development Method used
(1) Define and understand the problem and its causes Systematic review, content analysis, qualitative data
(2) Clarify which causal or contextual factors are malleable Logic model
(3) Identify the change mechanism Qualitative data
(4) Identify how to deliver the change mechanism Qualitative data, review of current DAs
(5) Test and refine on small scale Review by PPI and stakeholder groups
(6) Collect sufficient evidence of effectiveness to justify rigorous evaluation/implementation Feasibility  studya
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was used to develop the DA [18]. This theoretical frame-
work consists of three components: decisional needs; 
decisional support; and decisional quality. The frame-
work for the development and evaluation of decision 
aids for people considering taking part in a clinical trial 
outlined by Gillies and Campbell identified the ODSF 
as being a highly relevant theoretical framework to use 
when developing decision aids for trial participation [11]. 
This is because the ODSF asserts that decisional needs 
affect decisional quality, such as making informed and 
values-based choices, which in turn affect action, behav-
iour, and emotions such as regret [18]. These concepts 
are considered by Gillies and Campbell to map well onto 
the issues within trial participation decisions [11] which 
are known to be preference-sensitive decisions [31] as is 
also the case for proxy decisions.
In addition to ODSF, the International Patient Decision 
Aids Standards (IPDAS) framework of quality criteria 
for patient decision aids was used to guide the practi-
cal development of the decision aid [32]. This evidence-
informed framework provides a set of criteria which aims 
to improve decision aid content, development, imple-
mentation, and evaluation [32]. Alongside the IPDAS 
framework, a 44-item minimum standards ‘checklist’ 
version has been developed that is designed to rate the 
quality of the development process and decision-making 
design elements [33]. Relevant items from the IPDAS 
Minimal criteria v4.0 were used to inform the develop-
ment of this decision support intervention. Checklist 
items considered not relevant, and hence excluded from 
the development process, included: information relating 
to the condition or problem and associated probabilities 
as this would be included in the Participant Information 
Sheet provided about the study (and so would be used 
alongside the DA) and information related to screening 
or tests as this was not applicable.
IPDAS guidelines for the development of patient DAs 
recommend that they include a process for helping peo-
ple clarify their values [32]. These processes, usually 
termed values clarification methods (VCM), are defined 
as strategies intended to help individuals to evaluate the 
desirability of options or attributes of options within 
a specific decision context, in order to identify which 
option they prefer [34]. VCMs can be implicit and non-
interactive (e.g., the individual thinks about what is 
important to their decision), or explicit and interactive 
(e.g., using a rating scale for each attribute to reflect the 
importance of each to their decision) which is much 
more widely studied [34]. Whilst DAs have been found to 
be effective in reducing decisional conflict and increasing 
knowledge, the effect of specific strategies such as VCMs 
is less clear [35]. VCMs encourage patients to follow 
deliberative and analytical processes when comparing 
available choice options, although deliberation may not 
always be beneficial as it may overshadow important 
intuitive feelings that are more difficult to formulate but 
may be just as important in decision making [36]. How-
ever, the use of VCMs in DAs decision aids is now wide-
spread, with 57.1% of DAs in a recent systematic review 
including explicit methods to clarify values [10] and has 
therefore been included in this DA (further information 
is provided in the next section).
Review of existing decision aids for proxies
Although the search strategy for the systematic review of 
decision aids for trials specifically sought to include stud-
ies that included guardians of, or proxy decision makers 
for, potential trial participants, no existing decision aids 
for use by proxies have been identified [16]. However, a 
number of tools have been developed for proxies who are 
making other decisions on behalf of a person who lacks 
capacity, such as around the use of antipsychotic medica-
tion, place of care, retiring from driving due to demen-
tia, and receiving mechanical ventilation [15, 37–39]. 
The DAs intended for use by proxies invariably make 
the assumption that the evidence that decision tools are 
effective in increasing knowledge and reducing deci-
sional conflict is transferable to proxy decision-making, 
and there is some limited evidence of this. A small study 
examining the impact of a DA on proxy decision-makers’ 
perceptions of feeding options for people with dementia 
found it improved knowledge scores and reduced con-
flict [40]. A feasibility study of an intervention to support 
family carers making decisions about place of care for a 
person living with dementia also found that it reduced 
decisional conflict, although it did not remove all bar-
riers to decision-making and some unresolved conflict 
remained [37]. However, there is need for further trials to 
fully establish their effectiveness [25].
Phase 2: prior research which informed the intervention 
development
Clarifying the problem using the existing research evi-
dence and in consultation with stakeholders is consid-
ered to be the first step in intervention development 
[29]. Phase 2 built on a systematic review which was con-
ducted to synthesise the existing empirical evidence [8] 
which, together with a content analysis of information 
already provided to proxies [41], indicated that proxies 
are generally well provided with information about the 
study itself, but are not well informed about their role as 
proxy decision-maker. Whilst there is a paucity of litera-
ture regarding decision support for proxy decisions about 
research, the relationship between the parties involved 
appears to determine the kind of decision-making pro-
cess used and impacts on the way decisions are achieved 
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[42]. This decision support intervention therefore focuses 
on close family members acting as proxies, rather than 
others who can also legally act as proxy decision-makers 
for research such as members of the healthcare team [43].
We conducted a qualitative study with family members 
acting as proxies which showed that they use the patient’s 
expressed wishes about research where these are avail-
able and, where these were not known, use their in-depth 
knowledge of the person’s values and preferences to 
facilitate decision-making on their behalf [9]. However, 
other proxies described it as being a difficult and chal-
lenging decision. Improving the decision-making process 
was recognised as being much more than just ensuring 
the proxy had received adequate information. Proxies 
thought that greater decision support when consider-
ing research decisions would help in the future, which 
included orientating them towards considering the per-
son’s own views and preferences [9]. Proxies suggested 
that this support could take the form of a different sort 
of information sheet which covered their role as proxy 
decision-maker, and that the DA should include items 
that they considered would support proxies when making 
decisions about research (Table 2).
As the majority of the participants were proxies of 
someone living with dementia, the intervention was 
developed with this population as its focus, although 
there is no reason to suggest it would not be appropri-
ate for proxies of people with other conditions associated 
with cognitive impairment.
Collaborative development with stakeholders
Consultation with relevant stakeholders is an important 
step in the intervention development process [29]. This 
intervention was part of a larger project which benefitted 
from having the support of a lay advisory panel from the 
initial conception of the project through to the develop-
ment of the intervention itself. The lay advisory group, 
also known as a Public and Patient Involvement (PPI) 
group attended a discussion meeting to review the first 
draft of the decision aid, broadly following a cognitive 
debriefing approach to instrument development which 
can identify difficult or confusing areas of the item being 
reviewed and propose a better version [44]. The aim is 
also to identify whether the interpretation of an item dif-
fered between those reviewing it [44].
Additionally, a larger group of stakeholders was con-
vened and consulted who had experience as either a 
researcher who involves people who lack capacity in 
their research, family member who may be approached 
to act as a proxy, or those familiar with supporting family 
members of people with dementia. The importance of the 
involvement of practitioners and other stakeholders in 
developing and prototyping interventions, to ensure that 
they can be adopted, implemented and maintained in 
the contexts for which they are intended, is emphasised 
in many of the frameworks guiding intervention devel-
opment [29, 45]. Their role is important throughout the 
process, but particularly when determining the content, 
format, and delivery of the intervention [29]. Acceptabil-
ity of an intervention has been defined as ‘a multi-faceted 
construct that reflects the extent to which people deliver-
ing or receiving a healthcare intervention consider it to 
be appropriate, based on anticipated or experienced cog-
nitive and emotional responses to the intervention’ [46], 
and can be considered to have both cognitive and affec-
tive components [47]. This stage forms the ‘alpha’ testing 
of the intervention which is described as an iterative pro-
cess of testing by people directly involved in the develop-
ment process, and considered to be a necessary part of 
the development of decision aids [48].
Phase 3: development of a socio‑ecological model of proxy 
decision‑making
The term ‘complex interventions’ are primarily used to 
refer to interventions as system changes that are focused 
on health promotion, social interventions, and public 
health more broadly. Complexity is increasingly being 
conceived in terms of how interventions interact with 
their contexts, where contexts are broadly defined as any 
feature of the circumstances in which an intervention is 
conceived, developed, implemented and evaluated [45]. 
There is a call for intervention researchers to move away 
from viewing interventions as discrete bundles of com-
ponents which can be described in isolation from their 
contexts, and better understand the systems into which 
change is being introduced [49]. Thus there is a focus on 
Table 2 Items for inclusion in decision aid from the qualitative interview findings
1. Why people with cognitive impairment are included in research
2. That the proxy’s decision or advice should be based on what the person’s wishes and feelings about taking part would be if they had capacity to 
decide
3. That the proxy should consider if there is any reason why the person would not have wanted to participate
4. The relevant advantages and disadvantages and how they relate to the person themselves
5. That the person should be involved in the decision as much as possible
6. That the proxy can take time to decide and they can always change their mind
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interventions viewed as disruptions to complex systems, 
rather than on the intrinsic properties of interventions 
[50]. Decision aids, particularly this one to be used by 
proxies, can be considered to have properties of com-
plexity. It is a complex intervention with several interact-
ing components [51], entailing complex behaviours and 
a range of effects [52], and also as an event occurring 
within inevitably complex systems such as within a fam-
ily, legal and ethical frameworks, and a healthcare system.
Proxy decision-making for research, whilst not tradi-
tionally thought of as a behaviour, is similarly situated 
within complex systems which can be perceived as hav-
ing a number of levels which have contextually depend-
ent dynamic interactions between them. Developing a 
socio-ecological model (SEM) as phase 3 of the process 
was found to be a useful organising construct for proxy 
decision-making. It was adapted from the model most 
commonly used for health promotion and behaviour 
change interventions [53]. An ecological perspective 
recognizes that individuals are located within a broader 
social context [54, 55]. In this model, behaviour is con-
ceived as being determined by five levels of analysis: 
intrapersonal factors, interpersonal processes, com-
munity factors, institutional/organisational factors, and 
public policy or socio-cultural factors [56]. Developing 
the SEM enabled an exploration of the many different 
factors or levels involved, including the legal frameworks 
at both a policy and socio-legal level, the ethical govern-
ance processes involved, the knowledge and attitudes of 
the researcher and practitioner community, the interper-
sonal relationship between the proxy and the person they 
represent, which ultimately centre around the person 
who lacks capacity to consent. The main influences on 
the issue being examined were classified according to the 
socio-ecological model distinguishing between the differ-
ent levels of the model (Fig. 2).
In order to clarify which causal or contextual factors 
might have the greatest scope for change, a logic model 
[29] was iteratively developed (Additional file  1: Logic 
model for proxy decision support intervention). Logic 
models are an important tool for implementing a theory‐
based approach [57]. Logic models can help in areas of 
complexity by depicting intervention components and 
the relationships between them and displaying interac-
tions between the intervention and the system within 
which it is to be implemented [58].
Phase 4: develop prototype decision‑support intervention
A decision aid was developed for proxy decision-makers 
that would supplement the study-specific information 
contained in the Participant Information Sheet (PIS) and 
be delivered within a consultation with the researcher 
or clinician providing information about the research 
study or clinical trial. In addition to the need for decision 
support for proxies arising from the qualitative inter-
views, the previous research indicated that there were 
additional researcher/clinician informational needs that 
needed to be addressed. For the purposes of this inter-
vention, it suggested that an additional education and 
training component was required to provide informa-
tion about the legal frameworks to those who would be 
delivering the intervention. A short one-page guide to 
Fig. 2 Socio-ecological model of proxy decision-making for research
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the key messages of the decision support booklet was 
also developed as part of the intervention. The interven-
tion (the DA with an additional education component for 
the clinician/researcher undertaking recruitment) spans 
the individual-interpersonal-community spheres of the 
SEM of proxy decision-making. The aim of the interven-
tion was to improve informed decision-making by prox-
ies that better reflects the wishes and preferences of the 
person they represent, whilst ensuring it pays attention 
to the ethical principles and corresponds to the relevant 
legal frameworks (Fig. 3). The intervention also needed to 
be attentive to the informational needs of the healthcare 
professional, social care practitioner, or researcher who 
will be delivering the intervention to ensure that they are 
knowledgeable and confident in the inclusion of adults 
lacking capacity in research.
Format and content of the decision aid
A prototype of the DA was developed in phase 4 and 
iteratively refined following consultation with the lay 
advisory and stakeholder groups. The DA was presented 
as a 12-page A5 paper booklet which could be printed or 
read as a PDF document with ‘interactive’ features that 
encouraged proxies to identify the advantages and disad-
vantages of the research study being considered (Fig. 4).
The prototype DA was enhanced by a graphic designer 
to improve the accessibility and visual impact of the tool. 
A range of strategies were used to enhance reader under-
standing of the DA. Information was presented clearly 
and concisely using colour-coded sections to navigate 
the booklet. Readability scores [59] were assessed which 
showed that a Flesch Reading Ease score of 69.9 (fairly 
easy to read) was achieved and a Flesch-Kincaid Grade 
Level suggested that most 8th grade students (age 
13–14 years old) would be capable of reading the book-
let. Space, with prompts, was provided for notes and 
questions at various points in the booklet, and a space 
for additional questions was provided at the end of the 
booklet.
The content was presented in the order used in other 
examples of DAs for decisions about clinical trials [20, 
24]. This presented information about their role (includ-
ing clarifying whether they were being asked to provide 
advice or consent), understanding any advantages and 
disadvantages of participation, followed by structured 
guidance in deliberation or ‘making a decision’ that was 
adapted from existing clinical trial DAs [20, 24]. The sug-
gested decision-making process was through the six steps 
detailed in Fig. 5. adapted from Juraskova et al. [60]. This 
widely used DA component was included in order to pro-
vide some structure to the decision-making process that 
proxies felt they would benefit from [9].
This was then followed by an exercise which used val-
ues clarification methods (VCM) [36] to enable proxies 
to trade-off positive and negative features of the decision 
in order to facilitate decision-making that was personal 
and meaningful for the person being represented. As 
described previously, VCMs are commonly used in DAs 
and, given the challenges reported by proxies around 
establishing the research preferences of the person they 
Fig. 3 Location of intervention to support proxy decision-making for research in socio-ecological model
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were representing [9], the decision was made to include 
an explicit values clarification exercise in this DA. The 
original choice of visual metaphor for the VCM was a 
weighing scale, in line with existing DAs for clinical tri-
als [20, 24]. However, the VCM graphic was the area of 
the DA that most divided the opinions of the lay advisory 
group, where some members found the visual metaphor 
as the most valuable part of the DA and others strongly 
disliked the format. As there is a diverse array of VCMs in 
use, and the effectiveness of any given VCM is unknown 
[61], the metaphor was changed to an image that repre-
sented both direction and strength of response (Fig. 6).
Phase 5: assessing acceptability and comprehensibility 
of the decision aid
In order to establish the acceptability of the decision sup-
port tool, a stakeholder group was convened in phase 5 
of the development process. The stakeholder group was 
an opportunity to consult both those who represent the 
population who would receive the intervention and those 
who would be implementers. Nine participants attended 
a discussion and feedback event which was led with 
two co-facilitators. Six participants were researchers or 
research nurses in a range of fields including dementia, 
stroke, and Multiple Sclerosis, two had experience of car-
ing for a family member living with dementia, and one 
considered themselves to have prior experience as both a 
researcher and family carer.
A short acceptability questionnaire adapted from a pre-
vious developed acceptability tool [62] was completed by 
participants, and facilitated small discussion groups ena-
bled participants’ views to be explored in greater detail. 
The acceptability questionnaire showed that almost all 
participants felt that the decision support tool was the 
right length (89%, 8/9) and contained the right amount of 
information (78%, 7/9), and all participants thought that 
it would be useful. Open-text responses showed that par-
ticipants liked the simplicity of the language used and the 
presentation and ‘flow’ of the information. The colour-
coding of sections was thought to be particularly helpful, 
although different colour combinations were suggested 
that participants thought would increase the contrast and 
therefore the readability of the text. The prototype DA 
was subsequently refined following this feedback.
Fig. 4 Cover page and content list of the decision aid for family members making decisions about research
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The discussion groups revealed that participants 
viewed the format of the decision support tool positively, 
and participants were universally in favour of it being 
used within the context of a ‘consultation’ between the 
researcher and the family member(s) and as a supple-
ment to the Participant Information Sheet. It was thought 
to be both applicable and useful in a wide range of con-
texts beyond families of people living with dementia, 
Fig. 5 Six stage decision-making process detailed in the decision aid
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including in emergency or critical care settings requir-
ing deferred consent or a waiver where family members 
are approached once the emergency has passed to decide 
about the continued participation of a patient who lacks 
capacity. Participants felt that the information contained 
in the tool was well balanced about participation or non-
participation and the potential advantages and disadvan-
tages, and was viewed as empowering families to make an 
Fig. 6 Values clarification exercise included in decision aid
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informed decision. Participants recognised that the extra 
time burden or information burden for family members 
could act as a barrier but felt that this was offset with 
the importance of making informed decisions about the 
inclusion of those who lack capacity.
Further research to explore the feasibility and effective-
ness of the intervention is required. However, as this is 
the first decision support intervention aimed at enhanc-
ing proxy decisions about research, establishing which 
outcomes matter, to whom, and why has not previously 
been explored. Due to the differences in ‘self/other’ deci-
sion-making, outcomes for proxy decisions about trial 
participation may differ markedly from those reported in 
trials of interventions to improve informed consent for 
decisions about trial participation. Therefore, establish-
ing what conceptually constitutes ‘good’ proxy decisions 
about research, and the generation of a core outcome set, 
will support the development and subsequent evalua-
tion of interventions. Work to establish a core outcome 
set for interventions to enhance proxy decisions about 
research on behalf of adults who lack capacity to consent 
is underway (COnSiDER registered with Core Outcome 
Measures in Effectiveness Trials (COMET) Initiative 
www.comet -initi ative .org/studi es/detai ls/1409). Candi-
date measures may include outcomes such as prepared-
ness for decision-making, values-choice congruence, and 
decision conflict and regret.
Discussion
Following a growing focus on interventions to improve 
informed consent for research, the need for interven-
tions to improve proxy decisions about research has now 
been identified. This paper reports the development of 
the first such intervention. Informed by the decision-aid 
literature, theoretical frameworks, intervention develop-
ment frameworks, and our previous research exploring 
proxy decision-making for research, we have developed 
a new decision support intervention for families acting 
as proxy. Although the intervention (a DA plus an addi-
tional education component for the clinician/researcher 
undertaking recruitment) was primarily informed by 
research with families of people living with dementia, 
stakeholders indicated that it is appropriate for use by 
proxies of people with other conditions associated with 
cognitive impairment.
Conclusions
The decision aid is acceptable to both those who would 
be delivering and receiving the intervention, however 
formal feasibility testing is needed prior to an evalua-
tion of its effectiveness. As it is a novel intervention, fur-
ther work to develop and establish appropriate outcome 
domains and outcome measures is first required.
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